Risk Factors and Diagnosis of Advanced Cutaneous Squamous Cell Carcinoma

Gabriella Brancaccio¹, Giulia Briatico¹, Cristina Pellegrini², Tea Rocco², Elvira Moscarella¹, Maria Concetta Fargnoli²

¹ Dermatology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy
² Dermatology, Department of Biotechnological and Clinical Sciences, University of L’Aquila, L’Aquila, Italy.

Key words: advanced cutaneous squamous cell carcinoma, risk factors, prognostic factors, recurrence, metastasis

Citation: Brancaccio G, Briatico G, Pellegrini C, Rocco T, Moscarella E, Fargnoli MC. Risk factors and diagnosis of advanced cutaneous squamous cell carcinoma. Dermatol Pract Concept. 2021;11(S2): e2021166S. DOI: https://doi.org/10.5826/dpc.11S2a166S

Accepted: July 13, 2021; Published: September 2021

Copyright: ©2021 Brancaccio et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: None.

Corresponding author: Maria Concetta Fargnoli, MD, Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Coppito 2, L’Aquila, Italy. Email: mariaconetta.fargnoli@univaq.it

Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer affecting humans. The combination of the increasing incidence and high mortality in advanced stages of the disease, defines cSCC as an emerging public health problem. Advanced disease includes metastatic and locally advanced cSCC. Metastatic disease refers to the presence of locoregional metastasis (in transit or to regional lymph nodes) or distant metastasis. Locally advanced disease has been defined as non-metastatic cSCC that is unlikely to be cured with surgery, radiotherapy, or combination treatment. While metastatic cSCC is easily diagnosed, locally advanced disease lacks consensus definition and diagnosis is made after multidisciplinary board consultation. Identifying patients with aggressive cSCC at highest risk for relapse may prevent the occurrence of advanced disease. Prognostic factors suggested by most guidelines include tumor diameter (>2 cm), localization on temple/ear/lip/area, thickness (>6 mm), or invasion beyond subcutaneous fat, poor grade of differentiation, desmoplasia, perineural invasion, bone erosion, immunosuppression, undefined borders, recurrence, growth rate, site of prior metastasis.

ABSTRACT

Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer affecting humans. The combination of the increasing incidence and high mortality in advanced stages of the disease, defines cSCC as an emerging public health problem. Advanced disease includes metastatic and locally advanced cSCC. Metastatic disease refers to the presence of locoregional metastasis (in transit or to regional lymph nodes) or distant metastasis. Locally advanced disease has been defined as non-metastatic cSCC that is unlikely to be cured with surgery, radiotherapy, or combination treatment. While metastatic cSCC is easily diagnosed, locally advanced disease lacks consensus definition and diagnosis is made after multidisciplinary board consultation. Identifying patients with aggressive cSCC at highest risk for relapse may prevent the occurrence of advanced disease. Prognostic factors suggested by most guidelines include tumor diameter (>2 cm), localization on temple/ear/lip/area, thickness (>6 mm), or invasion beyond subcutaneous fat, poor grade of differentiation, desmoplasia, perineural invasion, bone erosion, immunosuppression, undefined borders, recurrence, growth rate, site of prior metastasis.
Introduction

Cutaneous squamous cell carcinoma (cSCC) is considered the second most common non melanoma skin cancer after basal cell carcinoma (BCC). Evidence indicates however that the incidence is still underestimated. Contrary to the reported BCC:SCC ratio of 4:1, a ratio of 1:1 was observed in the US Medicare fee-for-service Population from 2006 to 2012 [1], and an overall 263% increase in the incidence rate of SCC was observed from 1976 to 2010 in a population cohort from Minnesota [2].

cSCC is also regarded as the second most frequent cause of death due to skin cancer after melanoma, although, on a population-based scale, the absolute number of deaths from cSCC equals that of melanoma [3]. Despite the overall favorable clinical outcome of low risk cSCC, there is a subset of cSCCs that tends to recur and metastasize exhibiting a more aggressive course. The rate of recurrence varies from 2.7% [4] to 4.6% [5], as reported in 2 large studies including 653 and 985 patients with cSCC followed for approximately 10 years, respectively. The rate of metastases ranges from 1.2% to 4%, with 2.1% disease-specific death [5]. Because of the increasing incidence related to the aging population and the high mortality in advanced disease, cSCC is increasingly emerging as a public health problem.

The term “advanced cutaneous squamous cell carcinoma” defines cSCCs that are no longer amenable to surgery and/or radiotherapy (RT) and are eligible to anti PD-1 treatment [6]. The introduction of this class of drugs has raised awareness on advanced cSCC that was previously under-recognized and under-treated because of its poor prognosis. This draw attention towards the need for a clear and shared definition of advanced cSCC. However, the difficult management of advanced cSCCs requires that clinical and scientific efforts should be directed to prevent the occurrence of advanced disease. Risk assessment is therefore particularly important to identify the few cSCCs with a high risk of local recurrence or metastasis among all other low-risk tumors. High-risk cSCC should not turn into the advanced or metastatic form if properly managed with adequate surgery, follow-up, and adjuvant therapy. A thorough clarification of cSCC characteristics associated with poor prognosis is urgently needed, as it is crucial factor in guiding multidisciplinary discussions on an adequate management strategy.

Classification and Staging of cSCC

The WHO classification of skin tumors identifies several histologic variants of cSCC which have important implication for management and prognosis [7]. Among invasive cSCC, keratoacanthoma and verrucous SCC are considered low-grade variants as they have little, if any, metastatic potential, while acantholytic, spindle cell, adenosquamous, and clear cell SCC are characterized by a more aggressive behavior and worse prognosis [7].

The 8th edition of the TNM classification of malignant tumor (TNM8) was published in 2017, with a version from both the American Joint Committee on Cancer (AJCC) [8] and the Union for International Cancer Control (UICC) [9]. UICC and AJCC work closely together and, in most instances, the TNM version of each organization is the same or very similar. Unexpectedly, AJCC limited its TNM8 edition to the staging system for cSCC of the head and neck and did not provide a staging system for cSCC of the trunk and limbs. In comparison, UICC TNM8 provides 2 chapters for skin carcinoma: one covering the primary sites on the head and neck and one covering the trunk and limbs. Overall, the 2 chapters in UICC 8th and AJCC 8th ed. for cSCC TNM of head and neck are essentially identical except for the definition of perineural involvement (Tables 1-4) [9,10].

The T subcategory is defined by the clinical diameter and deep invasion of the primary tumor (with thresholds of 2 and 4 cm for clinical diameter and 6 mm as limit for deep invasion) and by perineural invasion or bone erosion as parameters of upgrade to T3 or T4a/b. However, the T2 subcategory comprises a wide range of tumors, some of them associated with poor prognosis [6]. The Brigham and Women’s Hospital (BWH) classification system for the T stage was developed to better correlate higher tumor stages with poor outcomes,
as an effort to more accurately separate high-risk from low-risk tumors [11]. In detail, this classification system identifies poor differentiation, perineural invasion, invasion beyond subcutaneous tissue and diameter ≥2 cm as risk factors associated with worse prognosis and provides a quantifiable risk value according to the number of identified risk factors. Thus, T2 tumors are stratified into a low-risk T2a stage (with one of the above risk factors) with 16% of these patients accounting for all SCC-related events (recurrence, nodal metastasis and/or death) and a high-risk T2b with tumors combining 2-3 risk factors and accounting for 64% of all SCC-related events. T3 stage includes tumors combining all 4 risk factors, as well as those with bone invasion.

The N subcategory is differently addressed in the 2 chapters of the UICC classification system (skin carcinoma of the head/neck and carcinoma of trunk/limbs) [9]. Unlike cSCC of trunk and limbs, cSCC of the head and neck incorporates extranodal extension and laterality into its staging criteria.

The combination of T, N, and M categories defines the stage of the tumor, with UICC and AJCC as the most wide-
spread and used staging systems (Table 5). Noteworthy, stage III in both UICC and AJCC staging systems includes cSCC, with or without nodal involvement, and stage IV includes cases with or without distant metastasis. These classifications seem to equate patients with advanced disease but with different characteristics. Likewise, both UICC and AJCC staging systems do not encompass all the potential risk factors for a worse prognosis of cSCC (eg location and differentiation) whereas a combination of prognostic factors should better guide management of cSCC in the multidisciplinary board.

Prognostic Factors in cSCC

Among the most authoritative guidelines for diagnosis and management of cSCC, EADO [12] and NCCN [13] guidelines, address the differentiation of high-risk from low-risk tumors (Table 6) (Figure 1). Prognostic high-risk factors proposed by EADO include tumor diameter (>2 cm), location on temple/ear/lip/area, thickness (>6 mm), or invasion beyond subcutaneous fat, poor grade of differentiation, desmoplasia, microscopic, symptomatic, or radiological perineural invasion, bone erosion, and immunosuppression. NCCN guidelines add as prognostic factors positive borders,
primary vs recurrent, growth rate, site of prior radiotherapy, lymphatic, or vascular involvement and, very recently, sub-classified cSCC into high-risk and very high-risk. Any high-risk factor places the patient in the high-risk category.

Risk factors associated with poor prognosis in cSCC can be classified as intrinsic (tumor-related) and extrinsic (patient- and physician-related) [6].

**Tumor-Related Prognostic Factors**

**Size.** Tumor diameter > 2 cm is the risk factor most associated with disease-specific death, with a 3-fold greater risk of recurrence and a 6-fold greater risk of metastasis [8].

A meta-analysis that included 36 studies and 17,248 patients set at 4 cm the most specific cutoff for determining the risk associated with tumor size [14]. Other studies have confirmed worse outcomes in T2 than in T1 tumors, but revealed that beyond the 2 cm cut-off, the effect on disease free survival (DFS) becomes smaller [15][16].

**Location.** cSCC of the ear, temples and lips are associated with higher risk of recurrence and metastasis compared to other body regions. The risk of nodal metastasis is 5-fold greater for cSCCs on the vermilion lip compared with those on the cutaneous lip. The absence of subcutaneous fat in the vermilion lip might allow quicker tumor access to the rich lymphovascular space of muscle leading to a greater metastatic potential [17]. Also, hands, feet, pretilial and anogenital area are considered location at risk independent of the size.

**Depth of invasion.** Concerning thickness, the cut-off to differentiate low-risk versus high-risk cSCC has been set at 6 mm, and it is unanimously reported by all the available staging systems, guidelines and meta-analyses [13,14,18]. When the depth of cSCC is reported as tumor invasion level, referring to the deepest tissue plan involved, the considered cut-off is the invasion beyond subcutaneous fat. Bone invasion is mentioned in many guidelines as an independent prognostic factor, as its presence upgrades to T3 (minor erosion) or T4 (gross invasion) according to the AJCC 8th ed. staging system. However, it is comprised, by definition, in the tumor invasion level.

---

**Table 4. pTNM Pathological Classification for Skin Carcinoma of the Head and Neck according to UICC 8th Edition**

| The pT categories correspond to the clinical T categories |
|---|---|---|
| pN – Regional Lymph Nodes | Histological examination of a selective neck dissection specimen will ordinarily include 10 or more lymph nodes. Histological examination of a radical or modified radical dissection specimen will ordinarily include 15 or more lymph nodes. |
| pNx | Regional lymph nodes cannot be assessed |
| pN0 | No regional lymph node metastasis |
| pN1 | Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension without extranodal extension |
| pN2a | Metastasis in a single ipsilateral lymph node, less than 3 cm in greatest dimension with extranodal extension, or more than 3 cm but not more than 6 cm in greatest dimension without extranodal extension |
| pN2b | Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, without extranodal extension |
| pN2c | Metastasis in bilateral or controlateral lymph nodes, none more than 6 cm in greatest dimension, without extranodal extension |
| pN3a | Metastasis in a lymph node more than 6 cm in greatest dimension without extranodal extension |
| pN3b | Metastasis in a lymph node more than 3 cm in greatest dimension with extranodal extension or multiple ipsilateral, or any contralateral or bilateral node(s) with extranodal extension |
| pM – Distant Metastasis | Distant metastasis microscopically confirmed |

**Table 5. Staging System for Both Skin Carcinoma (excluding eyelid, head and neck, perineal, vulva and penis) and Skin Carcinoma of the Head and Neck According to AJCC/ UICC 8th Edition**

| Stage | Tis | N0 | M0 |
|---|---|---|---|
| Stage 0 | T1 | N0 | M0 |
| Stage II | T2 | N0 | M0 |
| Stage III | T3 | N0 | M0 |
| | T1, T2, T3 | N1 | M0 |
| Stage IVA | T1, T2, T3 | N2, N3 | M0 |
| | T4 | Any N | M0 |
| Stage IVB | Any T | Any N | M1 |

---

**Figure**

![Diagnostic Ultrasound](image-url)
Perineural invasion. The impact of perineural invasion as risk factor for negative outcomes is the most well characterized. Many single institution reviews report a strong association with disease recurrence [15,17,19,20] and the meta-analysis by Thompson et al [14] confirmed a statistically significant association with disease-specific death and disease recurrence, with a risk ratio of 4.3 for disease recurrence. Thus, the AJCC 8th ed. upstages thin cSCCs to T3 if a nerve greater than 0.1 mm in caliber is involved [18].

Poor differentiation. The histologic grading system proposed by Broder in 1921 identifies 4 grades of differentiation according to the percentage of well-differentiated cells in the tumor tissue (Grade 1: 75% of well-differentiated cells; Grade 2: 50% of well-differentiated cells; Grade 3: 25% to 50% of well-differentiated cells; Grade 4: <25% of well-differentiated cells) [21]. Tumors are also classified into well-differentiated, moderately-differentiated, and poorly-differentiated according to the presence of clear keratinization, horn pearls, and other classic histologic features of cSCC, or the difficulty to determine a keratinocyte lineage [22]. The grade of histologic differentiation is not taken into account by the 8th edition of UICC and AJCC staging systems but remains a high-risk factor in the BWT system, NCCN, and EADO guidelines [6,11,13].

Desmoplasia. Desmoplastic cSCC is an aggressive histologic variant of cSCC characterized by narrow cords of cells and large amounts of extracellular stroma and often by perineural and perivascular invasion. Recurrence rate and metastatic potential are 10-fold and 6-fold higher than other cSCC variants, respectively [23].

Growth rate. It has been observed that a growth rate > 4 mm/month in the long axis of the tumor is associated with poor prognosis and a greater risk of lymph node metastasis [24]. However, only NCCN guidelines identify rapidly growing tumor among risk groups for local recurrence, metastases, or death from disease [13].

Extrinsic Prognostic Factors (Patient- and Physician-Related)

The role of extrinsic risk factors is more difficult to analyze, as features such as patient’s request to limit the extent of surgery or physician’s expertise in the treatment are impossible to standardize and systematically compare. However, in clinical practice, extrinsic factors have the greatest impact on the natural history of the tumor, as they may turn an early tumor with clinical and histological low-risk features into a cSCC with a high-risk of recurrence and worse outcome, namely an advanced cSCC.

Positive margins and recurrent disease. EADO guidelines do not include recurrence in the list of high-risk cSCC prognostic factors as it can be considered as the result of positive margins. Positive margins correspond to a residual tumor,
which has potential for recurrence a priori. When initial removal is incomplete, cSCC is more likely to recur, mostly locally and less frequently in regional lymph nodes [6]. In order to obtain optimal tumor clearance in cSCC < 2 cm in size, EADO suggests 5 mm clinically tumor-free margins, while in cSCC >2 cm in size suggested margins are 6-10 mm [6]. However, involved borders after the initial excision often derive from subclinical infiltration in sun-damaged skin [25]. Recurrent cSCC are twice as likely to recur after excisional surgery when compared with primary tumors [25].

Site of prior radiotherapy or chronic inflammatory process. cSCCs arising from a leg ulcer, burn scar, radiation dermatitis, discoid lupus, and other chronic wounds have a reported metastatic risk of 26% [26]. This risk factor is only listed by the NCCN guidelines.

Immunosuppression. The incidence of cSCC in immunosuppressed individuals has been estimated to be 64 to 250 times higher than in the general population. The cumulative incidence of cSCC increases progressively with duration of immunosuppression and tumors developed in this setting show a more aggressive behavior [27,28].

Comorbidities and patient’ preferences. Comorbidities represent one of the major obstacles to surgery, which is the first-line therapy of cSCC. Furthermore, in the case of high-risk tumors located on the head and neck area, primary excision can be often destructive, leading the patient to refuse the treatment. Patient’s request to limit extent of surgery is indeed an additional, substantial risk factor.

Managing Prognostic Factors - Practical Implications

Although numerous risk factors associated with worse outcomes have been identified, there is still a gap of knowledge on the precise risk of each factor individually. Combination of 2 or more factors is considered to significantly increase the risk of poor outcome. EADO guidelines recommend considering the variations of patient- and tumor-related characteristics when assessing the level of overall prognostic risk [6]. However, the decision still relies on the physician’ expertise and opinion, as neither a nomogram nor a scoring system are available yet to define which cSCC would deserve adjuvant RT or a closer follow-up program.
Adjuvant RT is offered as part of clinical practice in many medical centers for patients with high-risk cSCC, particularly for tumors with perineural invasion. However, there is still a lack of significant evidence, including randomized controlled trial data, showing a clear benefit of adjuvant RT in this setting [12].

There is no standardized follow-up schedule for patients with cSCC due to the lack of randomized controlled trials. Patients with high-risk cSCC should be followed up every 3-6 months for the first 2 years, and every 6-12 months for years 3-5, and annually thereafter [13]. Lymph node ultrasound should be performed every 3-6 months in the first 2 years depending on risk stratification. Again, as the independent prognostic effect of high-risk factors has not been consistently defined, EADO guidelines advice individual risk assessment to guide follow-up decisions [12].

**Diagnosis of Advanced Cutaneous Squamous Cell Carcinoma**

Advanced cSCC is classified as metastatic cSCC or locally advanced cSCC.

Metastatic disease includes locoregional metastasis (in transit or to regional lymph nodes) or distant metastasis which are easily diagnosed by imaging (stage III and IV according to AJCC /UICC 8th ed.). Noteworthy, the 8th ed. of AJCC/UICC staging system does not include the presence of in-transit metastases. The prognostic role of satellite and in transit metastasis in cSCC has been recently investigated by Xu et al [29] who found a significant association with worse overall survival.

Locally advanced cSCC has been defined as non-metastatic cSCC that is unlikely to be cured with surgery, radiotherapy, or combination treatment (surgery and radiotherapy) (Figure 2). However, locally advanced disease lacks consensus definition and diagnosis is made after multidisciplinary board consultation. Thus, the diagnosis of locally advanced cSCC is influenced by the expertise of each center. The need for standardized definition criteria of locally advanced cSCC is high in the clinical trial setting.

In phase 2 trial of cemiplimab for advanced cSCC, locally advanced cSCC patients were included if they experienced recurrence after 2 or more surgical procedures with subsequent unlikely curative resection, if the tumor already reached substantial local invasion precluding complete resection, or if surgical treatment would lead to substantial complications or deformity. Acceptable reasons for RT to be considered inap-

**Figure 2.** Locally advanced cutaneous squamous cell carcinoma (cSCC). (A) cSCC in a 83-year-old male patient, located on the right parietal region, no previous treatment, late diagnosis. (B) cSCC in a 77-year-old male patient on the left shoulder, recurrent to surgery. (C) cSCC on the leg of a 61-year-old immunosuppressed male, no previous treatment. (D) cSCC on the scalp of a 89-year-old male patient, recurrent after radiotherapy.
propriate were: previous RT with further RT exceeding the threshold of an acceptable cumulative dose, judgment of the radiation oncologist that the tumor was unlikely to respond to RT, or a risk–benefit assessment that RT was contraindicated for the patient [30].

Clinical progression of cSCC into the advanced form seems to be associated not only to the intrinsic aggressiveness of cSCC, but also to patient characteristics that may impact on clinician decision and incomplete tumor initial management.

Regarding real-life profile of advanced cSCC patients, a retrospective study by Hillen et al [3], analyzed 190 patients with advanced cSCC. Patients presented a median age of 78 years, an ECOG status 0-1, and location of the primary tumor most frequently on the head and neck, including high-risk locations such as ears or lips. Despite nonmalignant comorbidities influenced the decision for cSCC-specific therapy in only 21% of patients, the authors highlighted the fact that many clinicians might be unaware that locally advanced cSCC can lead to death. Eigentler et al [31], showed that in a cohort of 1,434 patients who excised a cSCC between 2005 and 2015 and were followed-up for a median period of 36.5 months, a higher number of patients died due to local infiltration in the head region or regional infiltration into neck lymph nodes, compared to death due to visceral metastases.

Concerning pitfalls of initial management of cSCC, a retrospective study by Deilhes et al [32], in a cohort of 109 patients with advanced cSCC, showed that 63% of patients had a delay of more than 3 months between the lesion’s first observation and biopsy, 62% of patients had incomplete histological examinations, and only 35% of patients completed all the procedures required for optimal management of the disease. Moreover, the authors highlighted that 75% of their patients’ cohort were living in rural areas and the decreased availability of dermatologists might have impacted mismanagement of the disease.

Conclusion

The clinician’s goal should be the recognition and appropriate treatment of cSCC at higher risk for recurrence and/or for progressing into advanced disease. However, it should be acknowledged that diagnosis, management, and follow-up of high-risk cSCC are still not straightforward. More studies are needed to standardize the relevance of each risk/prognostic factor, to explore the risk estimation of outcomes, and to prove the utility of disease-staging modalities. The adjuvant setting should be further explored to prevent progression of the disease. Currently, diagnosis and management of high-risk and advanced cSCC rely on a multidisciplinary approach that favors the most suitable therapeutic option based on the characteristics of the patient and of the disease.

References

1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatology. 2015;151(10):1081–6. DOI: 10.1001/jamadermatol.2015.1187. PMID: 25928283.
2. Muzic JG, Schmitt AR, Wright AC, Alnemi DT, Zubair AS, Olazagasti Lourido JM, et al. Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma. Mayo Clin Proc. 2017;92(6):890–8. DOI: 10.1016/j.mayocp.2017.02.015. PMID: 28522111.
3. Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCoG. Eur J Cancer. 2018;96:34–43. DOI: 10.1016/j.ejca.2018.01.075.
4. Brantsch KD, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–20. DOI: 10.1016/S1470-2045(08)70178-5. PMID: 18617440.
5. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: A 10-year, single-institution cohort study. JAMA Dermatology. 2013;149(5):541–7. DOI: 10.1001/jamadermatol.2013.2139. PMID: 23677079.
6. Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1: epidemiology, diagnosis and prevention. Eur J Cancer. 2020;128:60–82. DOI: 10.1016/j.ejca.2020.01.007. PMID: 32113941.
7. Murphy GF, Beer TW, Cerio R, et al. Squamous cell carcinoma. In: Elder DE, Massi D, Scolyer RA, Willemze R eds. WHO Classification of Tumours, 4th Edition. Lyon: IARC; 2018: 35-45.
8. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershewald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brower JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM ML. AJCC cancer staging manual. Eighth Edition. Switzerland: Springer; 2017. 171–81.
9. Brower JD, Gospodarowicz MK WCU for ICC. TNM Classification of Malignant Tumours Eighth Edition. Oxford: WILEY Blackwell; 2017. 131–138.
10. Koehane SG, Proby CM, Newlands C, Motley RJ, Nasr I, Mohd Mustapa MF, et al. The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K. Br J Dermatol. 2018;179(4):824–8. DOI: 10.1111/bjd.16892.
11. Jambusaria-Pahlajani A, Kanetsky PA, Karis P, Hwang W-T, Gelfand JM, Whalen FM, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatology. 2013;149(4):402–10. DOI: 10.1001/jamadermatol.2013.2456. PMID: 23323457.
12. Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83–102. DOI: 10.1016/j.ejca.2020.01.008.
13. NCCN. Squamous cell skin cancer Version 1.2021. Medlin Med Encycl. 2021; Accessed July 13, 2021. https://www.nlm.nih.gov/medlineplus/ency/article/000829.htm

14. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA dermatology. 2016;152(4):419–28. DOI: 10.1001/jamadermatol.2015.4994. PMID: 26762119.

15. Karia PS, Morgan FC, Califano JA, Schmults CD. Comparison of Tumor Classifications for Cutaneous Squamous Cell Carcinoma of the Head and Neck in the 7th vs 8th Edition of the AJCC Cancer Staging Manual. JAMA dermatology. 2018;154(2):175–81. DOI: 10.1001/jamadermatol.2017.3960. PMID: 29261835.

16. Trosman SJ, Zhu A, Nicollie EA, Leibowitz JM, Sargi ZB. High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: Risk Factors for Recurrence and Impact of Adjunct Treatment. Laryngoscope. 2021;131(1):E136–43. DOI: 10.1002/lary.28564. PMID: 32065413.

17. Wang DM, Kraft S, Rohani P, Murphy GE, Besaw RJ, Karia PS, et al. Association of nodal metastasis and mortality with vermillion vs cutaneous lip location in cutaneous squamous cell carcinoma of the lip. JAMA Dermatology. 2018;154(6):701–7. DOI: 10.1001/jamadermatol.2018.0792. PMID: 29801066.

18. Amin MB, Greene FL, Edge SB, Compton CC, Gershenson JD, Broockland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. DOI: 10.3322/caac.21388. PMID: 28094848.

19. Erkan S, Savundra JM, Wood B, Acharya AN, Rajan GP. Clinical perineural invasion of the trigeminal and facial nerves in cutaneous head and neck squamous cell carcinoma: Outcomes and prognostic implications of multimodality and salvage treatment. Head Neck. 2017;39(7):1280–6. DOI: 10.1002/hed.24607. PMID: 28474414.

20. Harris BN, Pipkorn P, Nguyen KNB, Jackson RS, Rao S, Moore MG, et al. Association of Adjunct Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2019;145(2):153–8. DOI: 10.1001/jamaoto.2018.3650. PMID: 30570645.

21. Broders A. Squamous cell cancer of the lip: a study of five hundred and thirty-seven cases. JAMA Dermatology. 1920;74:636-646. DOI: 10.1001/jama.1920.02620100016007.

22. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237–47. DOI: 10.1016/j.jaad.2017.08.059. PMID: 29332704.

23. Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP. Desmoplastic squamous cell carcinoma of skin and vermillion surface: a highly malignant subtype of skin cancer. Cancer. 1997;79(5):915–9. DOI: 10.1002/(sici)1097-0424(19970301)79:5<915::aid-cncr7>3.0.co;2-a. PMID: 9041153.

24. Cañieto J, Martín-Vallejo J, Cardenoso-Álvarez E, Fernández-López E, Pérez-Losada J, Román-Curto C. Rapid growth rate is associated with poor prognosis in cutaneous squamous cell carcinoma. Clin Exp Dermatol. 2018;43(8):876–82. DOI: 10.1111/ced.13570. PMID: 29756221.

25. Harris BN, Bayoumi A, Rao S, Moore MG, Farwell DG, Bewley AF. Factors Associated with Recurrence and Regional Adenopathy for Head and Neck Cutaneous Squamous Cell Carcinoma. Otolaryngol Neck Surg Off J Am Acad Otolaryngol Neck Surg. 2017;156(5):863–9. DOI: 10.1177/0194598117697053. PMID: 28322123.

26. Rowe DE, Carroll RJ, Day CLJ. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90. DOI: 10.1016/0190-9622(92)70144-5. PMID: 1607418.

27. Manyam BV, Gastman B, Zhang AY, Reddy CA, Burkey BB, Scharpf J, et al. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. J Am Acad Dermatol. 2015;73(2):221–7. DOI: 10.1016/j.jaad.2015.04.037. PMID: 26028324.

28. Garrett GL, Blanc PD, Boscardin J, Lloyd AA, Ahmed RL, Anthony T, et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA dermatology. 2017;153(3):296–303. DOI: 10.1001/jamadermatol.2016.4920. PMID: 28097368.

29. Xu MJ, Lazar AA, Garsa AA, Arron ST, Ryan WR, El-Sayed IH, et al. Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy. Head Neck. 2018;40(7):1406–14. DOI: 10.1002/hed.25114. PMID: 29524273.

30. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. J Clin Invest. 2020;126(2):294–305. DOI: 10.1172/JCI1470-2045(19)30728-4. PMID: 31952975.

31. Eigentler TK, Leiter U, Hafner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. Dermatology. 2019;235(6):516–21. DOI: 10.1159/000500636.